Application of serum SELDI proteomic patterns in diagnosis of lung cancer

BackgroundCurrently, no satisfactory biomarkers are available to screen for lung cancer. Surface-Enhanced Laser Desorption/ionization Time-of- Flight Mass Spectrometry ProteinChip system (SELDI-TOF-MS) is one of the currently used techniques to identify biomarkers for cancers. The aim of this study is to explore the application of serum SELDI proteomic patterns to distinguish lung cancer patients from healthy individuals.MethodsA total of 208 serum samples, including 158 lung cancer patients and 50 healthy individuals, were randomly divided into a training set (including 11 sera from patients with stages I/II lung cancer, 63 from patients with stages III/IV lung cancer and 20 from healthy controls) and a blinded test set (including 43 sera from patients with stages I/II lung cancer, 41 from patients with stages III/IV lung cancer and 30 from healthy controls). All samples were analyzed by SELDI technology. The spectra were generated on weak cation exchange (WCX2) chips, and protein peaks clustering and classification analyses were made using Ciphergen Biomarker Wizard and Biomarker Pattern software, respectively. We additionally determined Cyfra21-1 and NSE in the 208 serum samples included in this study using an electrochemiluminescent immunoassay.ResultsFive protein peaks at 11493, 6429, 8245, 5335 and 2538 Da were automatically chosen as a biomarker pattern in the training set. When the SELDI marker pattern was tested with the blinded test set, it yielded a sensitivity of 86.9%, a specificity of 80.0% and a positive predictive value of 92.4%. The sensitivities provided by Cyfra21-1 and NSE used individually or in combination were significantly lower than that of the SELDI marker pattern (P < 0.005 or 0.05, respectively). Based on the results of the test set, we found that the SELDI marker pattern showed a sensitivity of 91.4% in the detection of non-small cell lung cancers (NSCLC), which was significantly higher than that in the detection of small cell lung cancers (P < 0.05); The pattern also had a sensitivity of 79.1% in the detection of lung cancers in stages I/II.ConclusionThese results suggest that serum SELDI protein profiling can distinguish lung cancer patients, especially NSCLC patients, from normal subjects with relatively high sensitivity and specificity, and the SELDI-TOF-MS is a potential tool for the screening of lung cancer.

[1]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[2]  A. Stromberg,et al.  Identification of circulating antibodies to tumor‐associated proteins for combined use as markers of non‐small cell lung cancer , 2004, Proteomics.

[3]  Gonzalo Durante-Rodríguez,et al.  Proteomic analysis of lung biopsies: Differential protein expression profile between peritumoral and tumoral tissue , 2004, Proteomics.

[4]  X. Xiao,et al.  Development of Proteomic Patterns for Detecting Lung Cancer , 2004, Disease markers.

[5]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[6]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  S. Swensen,et al.  Lung cancer screening with CT: Mayo Clinic experience. , 2003, Radiology.

[8]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[9]  A Coldman,et al.  Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. , 1998, Chest.

[10]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[11]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[12]  B. Yalcin,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[13]  O John Semmes,et al.  Serum Protein Profiles to Identify Head and Neck Cancer , 2004, Clinical Cancer Research.

[14]  J. Kulpa,et al.  Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. , 2002, Clinical chemistry.

[15]  C. Chiu,et al.  Reduced Apoptosis in Newborn Compared to Adult Rat Intestine after Ischemia-Reperfusion Injury , 2004, Neonatology.

[16]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.